Targeting the brain--surmounting or bypassing the blood-brain barrier.
The constituents of the blood-brain barrier, including its efflux transporter system, can efficiently limit brain penetration of potential CNS therapeutics. Effective extrusion from the brain by transporters is a frequent reason for the pharmaceutical industry to exclude novel compounds from further development for CNS therapeutics. Moreover, high transporter expression levels that are present in individual patients or may be generally associated with the pathophysiology seem to be a major cause of therapeutic failure in a variety of CNS diseases including brain tumors, epilepsy, brain HIV infection, and psychiatric disorders. Increasing knowledge of the structure and function of the blood-brain barrier creates a basis for the development of strategies which aim to enhance brain uptake of beneficial pharmaceutical compounds. The different strategies discussed in this review aim to modulate blood-brain barrier function or to bypass constituents of the blood-brain barrier.
Potschka
Heidrun
H
Inst. of Pharmacology, Toxicology and Pharmacy, Ludwig- Maximilians-University Munich, Koeniginstr. 16, 80539 Munich, Germany. potschka@pharmtox.vetmed.uni-muenchen.de
D000818:Animals; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000008:administration & dosage
D004337:Drug Carriers; D004364:Pharmaceutical Preparations